-
24 November 2021
Selvita Group reports a dynamic increase in revenues for Q3 2021 YTD
-
22 September 2021
Selvita Group reports over 109% increase in revenues for H1 2021
-
21 September 2021
Selvita has received a grant to establish a technological platform, which will enable creation of new generation of drugs against diseases caused by coronaviruses
-
06 September 2021
Webinar: Screening in drug discovery best practices: past, present, and future
-
06 September 2021
Selvita will develop a platform to produce focused libraries of bioactive compounds with the use of machine learning and AI methods
-
19 July 2021
Selvita appoints Dean Bornilla as Vice President of Sales, Head of North America
-
12 July 2021
Selvita scales its operations with the construction of new research space
-
02 June 2021
Ardigen webinar – “AI methods in small molecule design.”
-
26 May 2021
Selvita Group reports over a two-fold increase in revenues for Q1 2021
-
24 May 2021
Fidelta Webinar – “Immunopathology and preclinical modelling of systemic lupus erythematosus (SLE)”
-
07 May 2021
Fidelta's Capabilities In Antiviral Drug Discovery
-
08 April 2021
Selvita Webinar – “Analytical outlook for biosimilar development”
-
30 March 2021
Breakthrough year in the development of Selvita – strategic acquisition & strong financial results
-
17 March 2021
Selvita will participate in the upcoming BIO-Europe Spring 2021
-
16 March 2021
Selvita named the Stock Exchange Company of the Year
-
04 March 2021
Selvita enters the mWIG40 index
-
24 February 2021
Selvita to present at the Precision In Drug Discovery & Preclinical Virtual Summit (West Coast)
-
09 February 2021
Selvita develops the cell-based phenotypic assay platform for drug discovery
-
20 January 2021
Webinar with live Q&A on modern small molecule drug discovery
-
04 January 2021
Selvita completes acquisition of Fidelta from Galapagos
